Analysts Set GlaxoSmithKline plc (LON:GSK) PT at $1,734.00

GlaxoSmithKline plc (LON:GSK) has earned an average recommendation of “Hold” from the twenty-two analysts that are covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is GBX 1,722.70 ($22.43).

A number of brokerages have recently weighed in on GSK. Berenberg Bank lowered their price target on GlaxoSmithKline plc from GBX 1,885 ($24.55) to GBX 1,835 ($23.90) and set a “buy” rating for the company in a report on Wednesday. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.74) price objective on GlaxoSmithKline plc and gave the company a “buy” rating in a research report on Tuesday, August 8th. Deutsche Bank AG set a GBX 1,610 ($20.97) price objective on GlaxoSmithKline plc and gave the company a “neutral” rating in a research report on Tuesday, August 8th. UBS AG set a GBX 1,600 ($20.84) price objective on GlaxoSmithKline plc and gave the company a “neutral” rating in a research report on Tuesday, August 1st. Finally, Shore Capital restated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Friday, July 28th.

TRADEMARK VIOLATION NOTICE: This story was first reported by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/13/glaxosmithkline-plc-longsk-receives-average-recommendation-of-hold-from-brokerages-updated.html.

GlaxoSmithKline plc (LON:GSK) traded down 0.57% during trading on Friday, reaching GBX 1475.00. 6,693,196 shares of the company’s stock traded hands. GlaxoSmithKline plc has a one year low of GBX 1,446.50 and a one year high of GBX 1,745.56. The firm’s market capitalization is GBX 72.10 billion. The company has a 50-day moving average price of GBX 1,589.13 and a 200 day moving average price of GBX 1,623.61.

The business also recently announced a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be given a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.

In related news, insider Victoria Whyte sold 4,820 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of GBX 1,693 ($22.05), for a total transaction of £81,602.60 ($106,267.22). Also, insider Patrick Vallance purchased 861 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The shares were acquired at an average cost of GBX 1,618 ($21.07) per share, for a total transaction of £13,930.98 ($18,141.66). Insiders have bought 3,151 shares of company stock worth $5,054,922 over the last ninety days.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply